[
  {
    "ts": null,
    "headline": "BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures",
    "summary": "Novo Nordisk A/S (NYSE:NVO) is among the most profitable healthcare stocks to buy. On January 26, BMO Capital lifted the price target on Novo Nordisk A/S (NYSE:NVO) to $57 from $47 and maintained a Market Perform rating. The firm highlighted flat prescription trends (TRx) for the company’s weight loss candidate Wegovy in the fourth quarter of […]",
    "url": "https://finnhub.io/api/news?id=c9b87c764055a43a8b2f0a29b909ad112e49630f57660a6ff808a5975cd0803b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769880949,
      "headline": "BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures",
      "id": 138316691,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S (NYSE:NVO) is among the most profitable healthcare stocks to buy. On January 26, BMO Capital lifted the price target on Novo Nordisk A/S (NYSE:NVO) to $57 from $47 and maintained a Market Perform rating. The firm highlighted flat prescription trends (TRx) for the company’s weight loss candidate Wegovy in the fourth quarter of […]",
      "url": "https://finnhub.io/api/news?id=c9b87c764055a43a8b2f0a29b909ad112e49630f57660a6ff808a5975cd0803b"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Faces Antitrust Scrutiny As Valuation Flags Undervaluation Risk",
    "summary": "U.S. House Judiciary Committee alleges CVS Health restricted independent pharmacies from using competing digital pharmacy hubs. The investigation cites cease and desist letters and network rule changes as potential antitrust issues. CVS Health disputes the findings and says some policies have been revised. For investors watching CVS Health (NYSE:CVS), the focus is shifting to regulatory risk around how its pharmacy network operates. The company’s shares closed at $74.52, with a return of...",
    "url": "https://finnhub.io/api/news?id=bcf146e559d6b78405d6a897501f06c2694aaa286e2e2e5ac185aa30ade3d628",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769872252,
      "headline": "CVS Health Faces Antitrust Scrutiny As Valuation Flags Undervaluation Risk",
      "id": 138315802,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "U.S. House Judiciary Committee alleges CVS Health restricted independent pharmacies from using competing digital pharmacy hubs. The investigation cites cease and desist letters and network rule changes as potential antitrust issues. CVS Health disputes the findings and says some policies have been revised. For investors watching CVS Health (NYSE:CVS), the focus is shifting to regulatory risk around how its pharmacy network operates. The company’s shares closed at $74.52, with a return of...",
      "url": "https://finnhub.io/api/news?id=bcf146e559d6b78405d6a897501f06c2694aaa286e2e2e5ac185aa30ade3d628"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Corporation (CVS) Positioned for Long-Term Growth Amid Policy Shifts",
    "summary": "CVS Health Corporation (NYSE:CVS) is one of the best healthcare stocks to buy for 2026. On January 27, BofA Securities cut its price target on CVS Health (NYSE: CVS) to $95 from $100 while keeping a Buy rating, citing CMS’s proposed CY 2027 Advance Notice policies that set a lower-than-expected net rate of 2.54%. The […]",
    "url": "https://finnhub.io/api/news?id=2903879bd8b0511dab6aede3ef341c38ec16db52bf67bfb6df326bfe1106bf73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769870154,
      "headline": "CVS Health Corporation (CVS) Positioned for Long-Term Growth Amid Policy Shifts",
      "id": 138315803,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "CVS Health Corporation (NYSE:CVS) is one of the best healthcare stocks to buy for 2026. On January 27, BofA Securities cut its price target on CVS Health (NYSE: CVS) to $95 from $100 while keeping a Buy rating, citing CMS’s proposed CY 2027 Advance Notice policies that set a lower-than-expected net rate of 2.54%. The […]",
      "url": "https://finnhub.io/api/news?id=2903879bd8b0511dab6aede3ef341c38ec16db52bf67bfb6df326bfe1106bf73"
    }
  },
  {
    "ts": null,
    "headline": "Argus Trims CVS Health (CVS) PT to $90 Amid Medicare Advantage Rate Uncertainty",
    "summary": "CVS Health Corporation (NYSE:CVS) is one of the most undervalued large cap stocks to invest in now. On January 28, Argus reduced its price target for CVS Health to $90 from $91 while maintaining a Buy rating. Despite a nearly 15% stock decline following the Centers for Medicare and Medicaid Services’ proposal for a flat […]",
    "url": "https://finnhub.io/api/news?id=6625ada96dc7ad79096050a16f8ebd251c0e8af4bf794317c97dee781249a1c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769863623,
      "headline": "Argus Trims CVS Health (CVS) PT to $90 Amid Medicare Advantage Rate Uncertainty",
      "id": 138315180,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "CVS Health Corporation (NYSE:CVS) is one of the most undervalued large cap stocks to invest in now. On January 28, Argus reduced its price target for CVS Health to $90 from $91 while maintaining a Buy rating. Despite a nearly 15% stock decline following the Centers for Medicare and Medicaid Services’ proposal for a flat […]",
      "url": "https://finnhub.io/api/news?id=6625ada96dc7ad79096050a16f8ebd251c0e8af4bf794317c97dee781249a1c1"
    }
  },
  {
    "ts": null,
    "headline": "The DGI Core Portfolio: 2025 Year-End Review",
    "summary": "The DGI Core Portfolio: 2025 Year-End Review",
    "url": "https://finnhub.io/api/news?id=e38a9974b47fdf124d7722526fb6b47b07c252956c3234c64c67d2b489b06471",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769847300,
      "headline": "The DGI Core Portfolio: 2025 Year-End Review",
      "id": 138314876,
      "image": "",
      "related": "CVS",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e38a9974b47fdf124d7722526fb6b47b07c252956c3234c64c67d2b489b06471"
    }
  }
]